• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Omada Health Inc.

    3/6/26 4:57:36 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care
    Get the next $OMDA alert in real time by email
    S-8 1 s-8.htm S-8 Document

    As filed with the U.S. Securities and Exchange Commission on March 6, 2026

    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    Omada Health, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    45-2355015
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification No.)

    611 Gateway Blvd, Suite 120
    South San Francisco, California 94080
    (888) 987-8337
    (Address of Principal Executive Offices) (Zip Code)

    Omada Health, Inc. 2025 Incentive Award Plan
    Omada Health, Inc. 2025 Employee Stock Purchase Plan
    (Full titles of the plans)

    Sean Duffy
    Chief Executive Officer
    Omada Health, Inc.
    611 Gateway Blvd, Suite 120
    South San Francisco, California 94080
    (888) 987-8337
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)
    Copies to:
    Nathan Salha
    Omada Health, Inc.
    611 Gateway Blvd, Suite 120
    South San Francisco, California 94080
    (888) 987-8337
    Kathleen M. Wells
    Richard Kim
    Latham & Watkins LLP
    140 Scott Drive
    Menlo Park, CA 94025
    (650) 328-4600
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”
    “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☐
    Emerging growth company☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Omada Health, Inc. (the “Registrant”) for the purpose of registering an aggregate of 3,644,941 shares of common stock, par value $0.001 per share (“Common Stock”), consisting of:

    i. 2,925,997 shares of Common Stock that were added on January 1, 2026 to the number of shares authorized for issuance under the Company’s 2025 Incentive Award Plan (the “2025 Plan”) pursuant to an “evergreen” provision, which allows for an annual increase in the number of shares of the Company’s Common Stock authorized for issuance thereunder;
    ii. 585,199 shares of Common Stock that were added on January 1, 2026 to the number of shares authorized for issuance under the Company’s 2025 Employee Stock Purchase Plan (the “ESPP”) pursuant to an “evergreen” provision, which allows for an annual increase in the number of shares of the Company’s Common Stock authorized for issuance thereunder;
    iii. 116,657 shares of Common Stock that expired, lapsed or were terminated, converted into an award in respect of shares of another entity in connection with a spin-off or other similar event, exchanged or settled for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited under the 2025 Plan or the Company’s 2011 Stock Plan (the “Prior Plan”), and as such again became available, in each case, as Common Stock for issuance under the 2025 Plan pursuant to its terms; and
    iv. 17,088 shares of Common Stock tendered or withheld in payment of the exercise price of an option under the 2025 Plan or any Prior Plan or tendered or withheld to satisfy any tax withholding obligation with respect to an award under the 2025 Plan or any Prior Plan, and as such again became available for issuance under the 2025 Plan pursuant to its terms.

    These additional shares of Common Stock are securities of the same class as other securities registered on the Registration Statement on Form S-8 relating to the same benefit plans filed with the Securities and Exchange Commission (the “SEC”) on June 6, 2025 (File No. 333-287823).

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 to be contained in the Section 10(a) prospectus is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).






















    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3.INCORPORATION OF DOCUMENTS BY REFERENCE
    The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:
    (a) the contents of the Registrant’s earlier Registration Statement on Form S-8 relating to the 2025 Plan and the ESPP, previously filed with the SEC on June 6, 2025 (File No. 333-287823);
    (b) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed
    with the SEC on March 6, 2026; and
    (c) the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-42679), filed by the Registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on June 3, 2025, including any amendment or report filed for the purpose of updating such description.
    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.





    ITEM 8.EXHIBITS
    Exhibit NumberIncorporated by ReferenceFiled
    Herewith
    Exhibit Description
    Form
    File Number
    Exhibit
    Filing Date
    4.1
    Restated Certificate of Incorporation
    8-K001-426793.16/9/2025
    4.2
    Amended and Restated Bylaws
    8-K001-426793.26/9/2025
    4.5
    Form of Common Stock Certificate
    S-1333-2871564.25/9/2025
    5.1*
    Opinion of Latham & Watkins LLP
    X
    23.1*
    Consent of Latham & Watkins LLP (included in Exhibit 5.1)
    X
    23.2*
    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    X
    24.1*Power of Attorney (included on the signature page to the Registration Statement)
    X
    99.1
    Omada Health, Inc. 2025 Incentive Award Plan
    S-1/A333-28715610.9(a)5/29/2025
    99.2(b)#
    Form Agreements under 2025 Incentive Award Plan
    S-1333-28715610.9(b)5/9/2025
    99.3#
    Omada Health, Inc. 2025 Employee Stock Purchase Plan
    S-1/A333-28715610.105/29/2025
    107.1*
    Filing Fee Table
    X

    *
    #
    Filed herewith.
    Indicates management contract or compensatory plan.





    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on this 6th day of March, 2026.
    OMADA HEALTH, INC.
    By:
    /s/ Sean Duffy
    Name:Sean Duffy
    Title:Chief Executive Officer

    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Duffy and Steve Cook, each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution and resubstitution, for him or her and in their name, place, or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ Sean Duffy
     Sean Duffy
    Chief Executive Officer and Director
    (Principal Executive Officer)
    March 6, 2026
    /s/ Steve Cook
     Steve Cook
    Chief Financial Officer
    (Principal Financial Officer)
    March 6, 2026
    /s/ Craig Gracey
     Craig Gracey
    Chief Accounting Officer
    (Principal Accounting Officer)
    March 6, 2026
    /s/ Jeryl Hilleman
    Jeryl Hilleman
    Chairperson of the Board of DirectorsMarch 6, 2026
    /s/ Anne Beal
    Anne Beal, M.D., M.P.H.
    DirectorMarch 6, 2026
    /s/ Trevor Fetter
    Trevor Fetter
    DirectorMarch 6, 2026




    /s/ Sachin Jain
    Sachin Jain, M.D.
    DirectorMarch 6, 2026
    /s/ Julie Klapstein
    Julie Klapstein
    DirectorMarch 6, 2026
    /s/ Jonathan Root
    Jonathan Root, M.D.
    DirectorMarch 6, 2026
    /s/ Adam Stavisky
    Adam Stavisky
    DirectorMarch 6, 2026




    Get the next $OMDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMDA

    DatePrice TargetRatingAnalyst
    1/9/2026$17.00Equal Weight
    Wells Fargo
    11/13/2025$27.00Outperform
    BMO Capital Markets
    9/5/2025$24.00Neutral
    Robert W. Baird
    7/1/2025$21.00Outperform
    Evercore ISI
    7/1/2025$25.00Overweight
    Morgan Stanley
    7/1/2025$19.00Overweight
    Analyst
    7/1/2025$23.00Buy
    Needham
    7/1/2025$21.00Overweight
    Barclays
    More analyst ratings

    $OMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Omada Health with a new price target

    Wells Fargo initiated coverage of Omada Health with a rating of Equal Weight and set a new price target of $17.00

    1/9/26 9:06:22 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    BMO Capital Markets initiated coverage on Omada Health with a new price target

    BMO Capital Markets initiated coverage of Omada Health with a rating of Outperform and set a new price target of $27.00

    11/13/25 9:15:29 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Robert W. Baird initiated coverage on Omada Health with a new price target

    Robert W. Baird initiated coverage of Omada Health with a rating of Neutral and set a new price target of $24.00

    9/5/25 8:00:48 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    SEC Filings

    View All

    SEC Form S-8 filed by Omada Health Inc.

    S-8 - Omada Health, Inc. (0001611115) (Filer)

    3/6/26 4:57:36 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by Omada Health Inc.

    10-K - Omada Health, Inc. (0001611115) (Filer)

    3/6/26 4:32:19 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Omada Health, Inc. (0001611115) (Filer)

    3/5/26 4:02:31 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Duffy Sean P. exercised 271,275 shares at a strike of $2.55 and sold $4,245,926 worth of shares (271,275 units at $15.65) (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    1/14/26 6:01:52 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Root Jonathan D was granted 915 shares, increasing direct ownership by 0.51% to 179,293 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    1/7/26 5:37:28 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Fetter Trevor was granted 991 shares, increasing direct ownership by 9% to 11,696 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    1/7/26 5:36:52 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Financials

    Live finance-specific insights

    View All

    Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026

    SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday, March 5, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-c

    2/9/26 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025

    SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced preliminary, unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Preliminary, unaudited revenue for the fourth quarter of 2025 is expected to be between $72 million and $74 million, representing an increase of 50% to 54% over the fourth quarter of 2024. For the full year 2025, preliminary revenue is expected to be between $256 million and $258 million, representing growth of 51% to 52% compared to 2024. Omada also announce

    1/12/26 9:07:17 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

    SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-conf.media-ser

    10/16/25 9:01:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

    SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associate

    11/4/25 12:00:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer

    SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology. In this role, he will lead Omada's clinical organization while advancing clinical quality, outcomes, strategy, and innovation across Omada's multi-condition platform. "Dr. Tsang's exceptional track record in building a virtual care delivery platform makes him the ideal clinical leader to help drive Omada's next phase of growth," said Sean Duffy, CEO and Co-Founder of Omada Heal

    10/27/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Launches "Meal Map," an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting

    The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada's Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence a

    10/1/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care

    SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first provider of between-visit care, today announced GLP-1 Flex Care, a new offering that will support employers looking to increase access to GLP-1 medications for obesity, including clinical evaluation, prescribing, and ongoing medical guidance and oversight. Members purchase their medications independently through cash-pay channels, helping employers limit their direct exposure to medication costs. Employee demand for GLP-1 medications continues to grow, but for many employers, the economics of full coverage remain out of reach.1 The majority of employers consider managing GLP-1 coverage and cost

    3/5/26 4:07:04 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Reports Fourth Quarter and Full-Year 2025 Results

    Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter and Full-Year HighlightsHighlights are for the fourth quarter and full year 2025, except where otherwise noted. Total members 886,000 at year end, up 55% year over year Revenue $76 million in the fourth quarter, up 58% year over

    3/5/26 4:03:55 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk

    SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol,1 yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level (<70 mg/dL).2 This gap underscores a core challenge in traditional care models that are not designed to sustain the day-to-day behaviors required to improve cholesterol numbers over time. "High cholesterol rarely exists in isolation1,3

    2/19/26 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care